Patents by Inventor Godfrey Jonah Anderson Rainey
Godfrey Jonah Anderson Rainey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059797Abstract: Provided herein are multispecific antigen binding proteins (ABPs). Also provided herein are multispecific ABPs that are engineered to form diabodies or stay in extended (dual scFv) conformation and methods for purifying ABPs based on avidity.Type: ApplicationFiled: July 29, 2021Publication date: February 22, 2024Inventors: Godfrey Jonah Anderson Rainey, Karin Jooss, Shan Liu Hwang, Gayatri Prakash, Isaac J. Rondon
-
Publication number: 20240000933Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.Type: ApplicationFiled: June 1, 2023Publication date: January 4, 2024Inventors: Godfrey Jonah Anderson Rainey, Wolfgang Walter Scholz, Ritsuko Sawada
-
Publication number: 20230295305Abstract: Provided herein are antigen binding proteins (ABPs) that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets and methods of treating cancers and other diseases using the disclosed ABPs.Type: ApplicationFiled: April 14, 2023Publication date: September 21, 2023Inventors: Godfrey Jonah Anderson Rainey, Karin Jooss, Roman Yelensky, Wade Blair, Heungnam Kim, Christine Janson, Anne Van Abbema, Isaac J. Rondon
-
Publication number: 20230287128Abstract: Provided herein are antigen binding proteins that selectively bind a particular KKLC-1 shared antigen, as well as related methods, kits, and compositions.Type: ApplicationFiled: August 17, 2022Publication date: September 14, 2023Inventors: Godfrey Jonah Anderson Rainey, Karin Jooss, Manankumar Anilkumar Shah
-
Patent number: 11707522Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.Type: GrantFiled: October 12, 2018Date of Patent: July 25, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Godfrey Jonah Anderson Rainey, Wolfgang Walter Scholz, Ritsuko Sawada
-
Publication number: 20220213196Abstract: Provided herein are HLA-PEPTIDE targets and antigen binding proteins that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets as well as identifying one or more antigen binding proteins that bind a given HLA-PEPTIDE target.Type: ApplicationFiled: August 16, 2019Publication date: July 7, 2022Inventors: Karin Jooss, Godfrey Jonah Anderson Rainey, Wade Blair, Michele Anne Busby, Jennifer Busby, Gijsbert Marnix Grotenbreg, Mojca Skoberne, Roman Yelensky
-
Publication number: 20220162320Abstract: Provided herein are HLA-PEPTIDE targets and multispecific antigen binding proteins that bind HLA-PEPTIDE targets. Provided herein is an isolated multispecific antigen binding protein (ABP), comprising: a first antigen binding domain (ABD) that specifically binds to a human leukocyte antigen (HLA)-PEPTIDE target; and an additional ABD that specifically binds an additional antigen, wherein the HLA-PEPTIDE target comprises an HLA-restricted peptide complexed with an HLA Class I molecule, wherein the HLA-restricted peptide is located in the peptide binding groove of an ?1/?2 heterodimer portion of the HLA Class I molecule, and wherein the HLA-PEPTIDE target is selected from Table A, Table A1, or Table A2.Type: ApplicationFiled: January 29, 2020Publication date: May 26, 2022Inventors: Karin Jooss, Godfrey Jonah Anderson Rainey, Wade Blair, Michele Anne Busby, Gijsbert Marnix Grotenbreg, Roman Yelensky, Shan Liu Hwang, Gayatri Prakash
-
Publication number: 20190111164Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.Type: ApplicationFiled: October 12, 2018Publication date: April 18, 2019Inventors: Godfrey Jonah Anderson RAINEY, Wolfgang Walter Scholz, Ritsuko Sawada
-
Patent number: 9889197Abstract: Diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The diabody molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The diabody molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule.Type: GrantFiled: July 29, 2011Date of Patent: February 13, 2018Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang, Godfrey Jonah Anderson Rainey
-
Patent number: 9096877Abstract: The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.Type: GrantFiled: October 7, 2010Date of Patent: August 4, 2015Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Godfrey Jonah Anderson Rainey, Sergey Gorlatov, Laura Lerner
-
Publication number: 20130295121Abstract: Diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The diabody molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The diabody molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule.Type: ApplicationFiled: July 29, 2011Publication date: November 7, 2013Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang, Godfrey Jonah Anderson Rainey
-
Patent number: 8404247Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: June 23, 2011Date of Patent: March 26, 2013Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Publication number: 20120219551Abstract: The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.Type: ApplicationFiled: October 7, 2010Publication date: August 30, 2012Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Godfrey Jonah Anderson Rainey, Sergey Gorlatov, Laura Lerner
-
Publication number: 20120156237Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: ApplicationFiled: June 23, 2011Publication date: June 21, 2012Applicants: THE SCRIPPS RESEARCH INSTITUTE, THE SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: JOHN YOUNG, ANETTE SCHNEEMANN, MARIANNE MANCHESTER, KELLY DRYDEN, JOHN M. MARLETT, DARLY JOSEPH MANAYANI, GODFREY JONAH ANDERSON RAINEY, VIJAY REDDY, MARC E. SILADI, HEATHER M. SCOBIE, DIANE THOMAS, MARK YEAGER
-
Patent number: 7998487Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: February 14, 2008Date of Patent: August 16, 2011Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Publication number: 20080299148Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: ApplicationFiled: February 14, 2008Publication date: December 4, 2008Applicants: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager